As the MELK gene is discovered to be responsible for Glioblastoma multiforme (GBM), OTSSP167, a MELK inhibitor recently in clinical trial phase I/II, has been synthesized for cancer treatment through MELK inhibition110. The gene discussed is MELK; the disease is glioblastoma.